ERNA logo

ERNEXA THERAPEUTICS INC

ERNANASDAQ
🏆 #5108 by market capEarnings Nov 5US Equity
$2.09▼ $0.01 (−0.48%)
Market closed · at close
🔔
Track ERNA
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 0.5%
7d▼ 0.5%
14d▼ 5.2%
30d▼ 35.3%
ytd▼ 93.2%
1y▼ 95.3%
🏦Market Cap
$3M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
83.5%
High
💵FCF Margin
283.5%
Strong
⚖️P/S Ratio
5.9x
Fair
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$2.08 – $2.08
52-Week Range
$1.84 – $71.50
Volume (shares)
394
Avg Volume (shares)
—
Shares Outstanding
1.6M
Next Earnings
2026-11-05

Fundamentals Snapshot

Annual Revenue
—
Last Q Revenue
—
P/E Ratio
—
P/S Ratio
5.9x
EPS (TTM)
$-25.77
Dividend Yield
0.58%
Dilution (1yr)
−84.7%
ERNA logo

ERNEXA THERAPEUTICS INC

ERNA
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▼ −100.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
83.5%▼ −133.8% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$9M▼ −40.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$7M▼ −56.5% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
314K▼ −84.7% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$1M▲ +$349K YoY
StockOtter · stockotter.space

About ERNEXA THERAPEUTICS INC

Ernexa Therapeutics Inc. is a biotechnology firm currently in its preclinical development phase, specializing in the creation of therapeutic interventions using induced mesenchymal stem cells (iMSCs). The company's primary focus lies in addressing solid tumor cancers and a range of autoimmune diseases. Its flagship candidate, ERNA-101, is an allogeneic iMSC designed to release pro-inflammatory cytokines, namely IL-7 and IL-15, intended for the treatment of ovarian cancer. Additionally, Ernexa is developing ERNA-102, an iMSC product engineered to secrete the anti-inflammatory cytokine IL-10, aimed at managing rheumatoid arthritis. The company has a licensing arrangement in place with Factor Bioscience Limited. Established in 2018, this Cambridge, Massachusetts-based entity operated as Eterna Therapeutics Inc. until its rebranding to Ernexa Therapeutics in March 2025.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💎Quality★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100

Analyst Ratings

ⓘ
Consensus
Buy
7 analysts
Strong Buy2
Buy4
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

News unavailable.